Business
Half Year Trading Update
Aptamer Group plc reported a 27% increase in revenue to £0.83 million for the six months ending December 31, 2025, with an FY26 fee-for-service order book exceeding £2.0 million and a sales pipeline of £3.1 million. The company has secured multiple licensing agreements, including with Twist Bioscience and Alphazyme, with initial commercial sales anticipated in the second half of FY26. Significant progress has been made with partners like Unilever and a top 3 pharmaceutical company for radioligand development, alongside repeat business from top-tier pharmaceutical partners totaling over £1 million in contract value with one partner. Aptamer also noted successful development of Optimer® IHC reagents with agreed royalties of 2% on net sales and positive preclinical characteristics for its fibrotic liver delivery vehicle. Disclaimer*
About this update from Aptamer Group Plc
[{"type":"text","content":"\n\n \n7 January 2026\n \nAptamer Group plc\n \n(\"Aptamer\", the \"Company\" or the \"Group\")\n \nHalf Year Trading Update\nRevenue up 27% to £0.83 million with an FY26 fee-for-service order book of over £2.0 million\nStrong sales pipeline of £3.1 million\nMultiple licensing opportunities in advanced stages already generating revenue\nContinued delivery on technical and commercial objectives to support financial strategy\n \nAptamer Group plc (AIM: APTA), the developer of next-generation synthetic binders for the life sciences industry, is pleased to announce a trading update for the six months ending 31 December 2025 (H1 26).\n \nFinancial performance\nAptamer's unaudited revenue for H1 26 is £0.83 million, representing a substantial 27% increase from the same period last year (H1 25: £0.65 million), and gives the Board confidence that full year revenue will materially exceed the prior year.\n \nThe Group has an FY26 fee-for-service order book of over £2.0 million in new contracts. In line with previous years, approximately 70% of this revenue is expected to be recognised during the financial year. In addition, the Group maintains a strong sales pipeline of £3.1 million as of today. The ongoing conversion and replenishment of this pipeline demonstrates the Group's ability to consistently convert opportunities into contracted revenue.\n \nStrategic progress towards a recurring revenue model\nThe Group is successfully executing its stated strategy of building a sustainable, high-margin business model through fee-for-service revenue and licensing partnerships. The period has seen significant acceleration in converting its proprietary technology and intellectual property (IP) into commercial licensing opportunities and executed agreements, marking a transition from development to commercialisation.\n \nLicensing Agreements\n· Two non-exclusive licensing contracts were signed in December 2025 with Twist Bioscience and Alphazyme, part of Maravai LifeSciences, delivering immediate upfront payments with ongoing revenues through milestone payments, royalties and manufacturing income. The first commercial sales are anticipated in H2 26.\n \n· A third partner, a global manufacturer of a specific enzyme, is currently ev...